Core Insights - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for neurodegenerative disorders, particularly Alzheimer's disease and dementia with Lewy bodies [4] Group 1: Workshop and Presentation - Dr. Mary Hamby will co-host a precision medicine workshop at the Hanson Wade Neuroimmunology Drug Development Summit, focusing on participant screening methods for clinical trials [1] - The workshop will include an overview of findings from Cognition's Phase 2 'SHINE' study of zervimesine (CT1812), highlighting that participants with lower p-tau217 levels showed a 95% improvement on the ADAS-Cog 11 scale and a 108% improvement on the MMSE scale compared to placebo [2][3] Group 2: Diagnostic Potential - Plasma p-tau217 assays are suggested to be valuable not only as a diagnostic tool but also for identifying Alzheimer's patients who are most likely to benefit from therapies targeting beta amyloid [3] - The measurement of plasma p-tau217 can be conducted through a simple blood test, aiding in the personalization of treatment regimens for patients [3] Group 3: Company Overview - Cognition Therapeutics is currently investigating zervimesine in clinical programs for dementia with Lewy bodies and Alzheimer's disease, including the ongoing START study in early Alzheimer's disease [4] - Zervimesine is believed to interact with the sigma-2 receptor, offering a distinct mechanism for treating degenerative diseases [4]
Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit